Drug-eluting stents for the treatment of in-stent restenosis: a clinical review

Treatment of in-stent restenosis (ISR) remains problematic despite the widespread application of drug-eluting stents (DES). Challenging lesion cohorts such as diffuse ISR and restenosis after failed intracoronary radiation therapy (IRT) maybe best treated with DES. The overall benefit of DES appears...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cardiovascular revascularization medicine 2005-01, Vol.6 (1), p.38-43
Hauptverfasser:	Yan, Bryan P Y, Ajani, Andrew E, Waksman, Ron
Format:	Artikel
Sprache:	eng
Schlagworte:	Antibiotics, Antineoplastic - administration & dosage Antibiotics, Antineoplastic - therapeutic use Antineoplastic Agents, Phytogenic - therapeutic use Coated Materials, Biocompatible - therapeutic use Coronary Restenosis - therapy Humans Paclitaxel - therapeutic use Sirolimus - administration & dosage Sirolimus - therapeutic use Stents
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Treatment of in-stent restenosis (ISR) remains problematic despite the widespread application of drug-eluting stents (DES). Challenging lesion cohorts such as diffuse ISR and restenosis after failed intracoronary radiation therapy (IRT) maybe best treated with DES. The overall benefit of DES appears inferior to their utility in treating de novo coronary lesions. Randomised trials comparing DES and IRT will soon be available to determine the optimal therapy for ISR. The challenge to treat ISR in the DES era is the next frontier of interventional cardiology.
ISSN:	1553-8389
DOI:	10.1016/j.carrev.2005.04.003